Kornimate/medical-research-clean huggingface dataset:
gwas in nmdar encephalitis

Conditions: Autoimmune Encephalitis

Summary: autoimmune encephalitis are characterized by the subacute development of memory deficits, altered mental status, and psychiatric symptoms, generally in association with anti-neuronal antibodies. two main groups of autoimmune encephalitis may be distinguished based on the location of the targeted antigen: 1) intracellular antigens, in which the antibodies are thought not to be pathogenic, and the disorders are usually strongly associated with cancer, constituting therefore paraneoplastic neurological syndromes; 2) synaptic proteins and surface receptors, in which the antibodies are pathogenic and the frequency of cancer is variable depending on the antibody and the demographic characteristics of the patient. encephalitis with antibodies against n-methy-d-aspartate receptor is the most common autoimmune encephalitis, being even more frequent than infectious etiologies. it is characterized by subacute onset of memory deficits, psychiatric symptoms, speech dysfunction, seizures, movement disorders, decreased level of consciousness, dysautonomia and central hypoventilation. nearly 50% of women with anti-nmdar encephalitis have an ovarian teratoma, while associated tumors in elderly patients are usually carcinomas. in contrast, most cases in children and young men are non-paraneoplastic. recently, herpes-simplex encephalitis has been described as another trigger of nmdar encephalitis. conversely, for the vast majority of the non-paraneoplastic autoimmune encephalitis, no acquired triggers have been described so far. in addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of autoimmune encephalitis. the human leukocyte antigen (hla) is the genetic factor most frequently associated with autoimmune diseases, and it has been already linked to a few autoimmune encephalitis, such as anti-leucine rich glioma inactivated 1 (lgi1), contactin-associated protein-like 2 (caspr2), iglon5, and glutamic acid decarboxylase 65 (gad65) encephalitis. however, no hla association has been reported for nmdar encephalitis, suggesting that in this condition, and likely in others, non-hla loci might be involved in the pathogenesis as well. genome-wide association studies (gwas) are useful tools to identify variants at genomic loci that are associated with complex diseases, and in particular, to detect associations between single-nucleotide polymorphisms (snps) and diseases. the aim of the study is to detect genetic variants in nmdar encephalitis and other autoimmune encephalitis.


Eligibility criteria:
inclusion criteria: * presence of well-characterized antibodies in serum or cerebrospinal fluid; * clinical picture compatible with the detected antibody based on the literature exclusion criteria: * absence of complete clinicobiological data. * alternative diagnosis

Keywords: autoimmune encephalitis paraneoplastic neurological syndromes nmdar
bariatric surgery and pharmacokinetics of apixaban

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study we investigate the pharmacokinetic effects of bariatric surgery on apixaban.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics apixaban
study to evaluate the safety and efficacy of adalimumab in chinese subjects with moderate to severe crohn's disease

Conditions: Crohn's Disease

Summary: this study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active crohn's disease in china.


Eligibility criteria:
inclusion criteria: * subjects of chinese descent with full chinese parentage. * diagnosis of crohn's disease (cd) for at least 3 months prior to week 0. * crohn's disease activity index (cdai) greater than or equal to 220 and less than or equal to 450 despite treatment with oral corticosteroids and/or immunosuppressants. * subject has a negative tuberculosis (tb) screening assessment. * subject has elevated high sensitivity c-reactive protein (hs-crp) during the screening period. exclusion criteria: * subject with ulcerative colitis or indeterminate colitis. * subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future. * subject with an ostomy or ileoanal pouch. * subject who has short bowel syndrome. * subject with symptomatic known obstructive strictures. * subject with an internal or external fistula (with the exception of an anal fistula without abscess). * active, or chronic or recurring infections, or active tuberculosis.

Keywords: china tumor necrosis factor (tnf)-alpha biologic
predictors of pain relief in chronic pancreatitis undergoing eswl

Conditions: Chronic Pancreatitis

Summary: extra corporeal shock wave therapy (eswl) is recommended for pain management in patients with stone formation in pancreatic duct. eswl can cause complete stone fragmentation and removal in 70% patients, associated with 85 to 90% pain relief. investigators aim to study, predictors pain relief in patients who undergo eswl, to find out which patients will improve and which patients won't improve in terms of pain.

the study will be a single center observational study. general information of the patient in form of duration of symptoms and duration of diagnosis,exocrine and endocrine insufficiency. imaging findings such as main pancreatic duct stone,size,parenchymal calcification , ductal stricture and its location, using any medications such as antioxidants and pain killers . the pain score will be estimated by izbicki's pain score in last 6 months. patients will receive standard of care during study period, and they won't receive any experimental therapy. after 6months of eswl further general information of the patient any addictions, a formal imaging and determining main pancreatic duct stone ,size ,calcifications and strictures and also usage of any medications for decreasing pain. pain will be calculated by izbick's pain score in last 6 months . comparing pain score and information investigators will evaluate predictive factors of pain relief after eswl by logistic regression.

Eligibility criteria:
inclusion criteria: * chronic pancreatitis patients undergoing eswl exclusion criteria: * patients with multiple pancreatic duct stones * patients with multiple pancreatic duct strictures * pancreatic head mass * patients with ascites * pregnancy * patients not giving consent for participation * pseudocyst
slow expansion and protraction in cleft lip and palate patients

Conditions: Cleft Lip and Palate

Summary: evaluate the treatment outcome of slow maxillary expansion protocol on patients with cleft lip and palate, using a differential opening expander and face mask which will be measured and recorded by cone beam computed tomography (cbct).

cleft lip and palate are among the most common deformities in children. cleft patients are usually having orofacial problems as missing or unerupted permanent teeth, alveolar bone defect, speech difficulty. patients with cleft lip and palate (clp) commonly have maxillary arch constriction (maxillary hypoplasia) and class iii malocclusions due to deficient of maxillary growth. the upper jaw of patients with cleft palate will be expanded using maxillary expander with differential opening (edo) which has two screws; one anterior and one posterior. this will be done with slow expansion protocol, which is one 1/4 turn three times weekly. petit facemask will be used to protract the retracted maxilla. the differences in measurements between before and after treatment will be assessed by cone beam computed tomography (cbct).

Eligibility criteria:
inclusion criteria: * all patient age ranges from 8 to 12 years. * patients of both sexes. * cleft lip and palate patients. * all the cases showed maxillary arch constriction and deficiency. * all patients had maxillary permanent first molars. * primary lip adhesion and palatal closure. exclusion criteria: * patients had received any surgical assisted rapid maxillary expansion or maxillary protraction of fixed orthodontics before. * maxillary dentition unsuitable to bond the expander (less than two dental units beside permanent first molar). * absent maxillary permanent first molars. * uncooperative patients/parents.

Keywords: cleft lip and palate expansion slow expansion maxillary expander with differential opening (edo) protraction face mask cone beam computed tomography (cbct)
proteogenomic signatures analysis in ovarian cancer

Conditions: Ovarian Cancer

Summary: proteogenomic analysis to detect individual platinum-induced modifications on tumor tissue of hgsc according to chemotherapy response score (crs), using a combined approach of high resolution liquid chromatography mass spectrometry based platform (hr-lc-ms/ms and advanced immunometric methods on illumine platform); multiple supervised machine learning algorithms will be used to discover proteogenomic signatures and biological processes associated with platinum modification during the neoadjuvant chemotherapy treatment. these results contribute to precision medicine by building an accurate proteogenomic profile of ovarian cancer, in order to better understand the underlying mechanisms of different chemotherapy response among affected patients.


Eligibility criteria:
inclusion criteria: newly diagnosed advanced international federation of gynecology and obstetrics (figo) stage iii a or greater epithelial ovarian cancer addressed to neoadjuvant chemotherapy (nact) and interval debulking surgery (ids); availability of freshly frozen tissue and ffpe tissue from both exploratory laparoscopy (baseline) and ids; age between 18 and 80 years; estimated life expectancy of at least 4 weeks; signed informed consent exclusion criteria: non-serous histology at frozen section; patients with a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (\> 10 mg equivalent prednisone/daily) or any other form of immunosuppressive therapy within 7 days prior to the enrollment; previous diagnosis of cancer within 5 years.
acute kidney injury and acute kidney disease in covid-19

Conditions: Acute Kidney Injury; Corona Virus Infection

Summary: acute kidney injury (aki) has been identified as an independent risk factor for in-hospital mortality. the present study aims to investigate the incidence of aki and renal recovery of inpatients diagnosed with covid-19.

beginning in december 2019, a novel coronavirus, designated as severe acute respiratory distress coronavirus 2 (sars-cov-2), has caused an international outbreak of respiratory illness termed coronavirus disease 2019 (covid-19). although the clinical manifestations of covid-19 are dominated by respiratory symptoms, some patients show severe kidney abnormalities. acute kidney injury (aki) has been identified as an independent risk factor for in-hospital mortality. the present study aims to investigate the incidence of aki and renal recovery of inpatients diagnosed with covid-19.

Eligibility criteria:
inclusion criteria: 1) patients with covid-19 diagnosed by world health organisation (who) criteria exclusion criteria: 1. patients aged less than 18 years 2. patients with stage 4 chronic kidney disease (baseline estimated glomerular filtration rate \<30 ml/min/1.73 m2) 3. patients receiving maintenance dialysis 4. recipients of solid-organ transplantation
safety and efficacy study of topical methyaminlevulinate (mal) in subjects with facial acne

Conditions: Acne

Summary: a study of safety and efficacy of topical methyaminlevulinate 80mg/g with and without occlusion followed by red light exposure in subjects with facial acne.

photocure asa has developed a cream formulation containing methyl aminolevulinate (mal), an ester of ala. there is extensive experience with the safety of mal-pdt in humans. this study will assess safety and efficacy of four treatments with methylaminolevulinate (mal) at 80 mg/g performed with and without occlusion and followed by red light exposure 90 minutes later in subjects with facial acne vulgaris. subjects will be randomized to one of two groups of 20 subjects: group 1 will receive 25 j/cm2 of red light (45 mw/cm2) and group 2 will receive 37 j/cm2 of red light (90 mw/cm2). for each subject one side of the face will be randomized to receive mal for 90 minutes without occlusion and the other side of the face will receive mal for 90 minutes with occlusion.

Eligibility criteria:
inclusion criteria: * subject willing to use an adequate contraceptive method or is surgically sterile, post menopausal, abstinent or with a same-sex partner. adequate means of contraception include; iud in use 30 days prior to day 0, barrier methods and spermicide in use atleast 14 days prior to day 0 or oral contraceptive in use for at least 6 months prior to day 0 * age 18 or older * capable of giving informed consent * diagnosis of acne vulgaris on the face with at least 10 inflammatory lesions on both sides of the face at screening and day 0 * global acne severity assessment score ≥ 3 at the screening and day 0 visit. exclusion criteria: * allergy to methylaminolevulinate or any component of the vehicle * acne fulminans or conglobata on the face * clinical significant sensitivity to visible light, porphyria or porphyrin sensitivity * use of any topical treatment for acne on the face within the previous 2 weeks before day 0 * any use of systemic antibiotics within 1 month prior to day 0 or use of isotretinoin within 1 year prior to day 0 * exposure to ultraviolet radiation (uvb phototherapy, sun tanning salons) within 4 weeks of day 0 * use of any investigational drug within 4 weeks of day 0 * alcoholism or drug abuse in the past year * any unstable or serious medical condition at the discretion of the investigator * current pregnancy or lactation * use of hormonal contraceptives solely for control of acne * current use of oral contraceptives (unless subject is on a stable dose e.i. at least six months of treatment prior day 0), testosterone or any other systemic hormonal treatment * any serious dermatological disorder, including malignancies that would either put the subject at risk or interfere with efficacy or safety evaluations * fitzpatrick phototype v or vi (inadequate penetration of red light in dark skin subjects) * subjects with extensive facial hair (e.g. beard) that would either impair red light exposure or interfere with lesion evaluation.
dyslipidemia and diabetic retinopathy

Conditions: Diabetic Retinopathy; Dyslipidemia

Summary: the purpose of this study is to determine if the reparative cells of blood vessels called endothelial progenitor cells(epc) are defective in people with diabetes.

the purpose of this study is to determine if the reparative cells of blood vessels, called endothelial progenitor cells (epc's) are defective in people with diabetes. diabetic retinopathy (dr) is an eye disease related to diabetes. it can cause blurred vision and possible bleeding in the blood vessels in the back of the eye (retina). damage to the cells of the blood vessels from dr can cause vision loss or blindness. even with current treatments, the quality of life for people with dr is much reduced.

Eligibility criteria:
inclusion criteria: * any man or woman * greater than 18 years of age * diagnosis of diabetes (applies to the diabetic arm only) (n=15 type 1 and n=15 type * the subject must be willing and have the ability to cooperate with the protocol. children will not be eligible because the investigators need to obtain 150 ml of blood and this is in excess of what can be drawn in children. exclusion criteria: * female participants must not be pregnant at the time of the blood draw as evident through a dipstick pregnancy test. * have retinal abnormalities other than diabetic retinopathy.
feasibility and outcomes of complete coronary revascularization using bvs in all-comer patients with angina

Conditions: Angina

Summary: the aim of the study is feasibility of complete coronary revascularization with bioresorbable vascular scaffold (bvs) implantation and assessment of treatment outcomes in a group of consecutive patients with stable and unstable angina in russian population. the hypothesis of this registry study: 1) complete coronary revascularization with bvs implantation will be feasible to perform in at least 70 percent of patient population with stable and unstable angina qualified for revascularization after coronary angiography, 2) complete revascularization with bvs is as safe and effective as revascularization with standard bms (bare metal stent bms/ drug eluting stent des stent implantation (published literature comparators in matched populations). up to 2500 patients will be enrolled in 13 russian high volume invasive cardiology centres. 12 month clinical observation and 5-year clinical follow-up is expected.

study design: data regarding all consecutive patients qualified for revascularization (pci percutaneous coronary intervention or cabg coronary artery bypass grafting) will be collected in this prospective study. information regarding revascularization strategy will be collected as detailed information concerning pci procedure. in case of pci with other than bvs stent implantation (bms or/and metallic des) information collected in the study will contain at least: * reason why bvs was not implanted * final result of baseline treatment * acute and long-term outcome of treatment (12 month clinical observation); nb. 5-year clinical follow-up is also expected. the enrollment phase of the registry is not expected to last longer than 12 months.

Eligibility criteria:
inclusion criteria: patient characteristics * age \> 18 years * able and willing to give informed consent * willing to comply with specified follow-up evaluations * clinical manifestation of coronary artery disease: stable angina or unstable angina * indications for coronary revascularization exclusion criteria: patient characteristics * acute myocardial infarction * cardiogenic shock * any reason for patient's inability to comply with 12-month double antiplatelet therapy (dapt) * absolute contraindications to des or bvs implantation

Keywords: stable and unstable angina bioresorbable vascular scaffold bvs pci
biofeedback for adolescent cannabis use disorder

Conditions: Adolescent Cannabis Use Disorder

Summary: the aims of this study are: 1) to estimate the effect size of hrv biofeedback for stress in adolescents undergoing cognitive behavioral therapy (cbt) for cannabis use disorder (primary outcome: perceived stress scale) and 2) to estimate the effect size of hrv biofeedback for cannabis use in adolescents undergoing cbt for cannabis use disorder (primary outcome: number of days used cannabis in the past 30 days).


Eligibility criteria:
inclusion criteria: * be between the ages of 13 and 19 years, with a parent or legal guardian available to complete parental assessments, if the participant is a minor * meet diagnostic and statistical manual of mental disorders, 5th edition, (dsm-v) criteria for cannabis use disorder by clinical interview; * be medically healthy; * be willing to participate in the study intervention and assessments; * plan to live locally for at least 4 months; * be able to read english well enough to complete study questionnaires; * have self-reported cannabis use in the past 28 days; * have a perceived stress scale score \> 20. exclusion criteria: * current or past psychosis; * bipolar i or ii disorder; * the need to take psychotropic medications at any time during the study; * pregnancy; * psychiatric or substance use disorder that cannot be managed with outpatient care (e.g. alcohol withdrawal, severe major depressive disorder, significant suicidal ideation); and * medications known to affect hrv (e.g. albuterol, pseudoephedrine, beta adrenergic blockers).

Keywords: adolescent cannabis biofeedback
wand study - a study to evaluate fuzeon (enfuvirtide) administered by a needle-free injection device in patients with hiv.

Conditions: HIV Infections

Summary: the purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer fuzeon, compared with the standard needle/syringe supplied with commercial fuzeon. the anticipated time on study treatment is \<3 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * male or female patients, \>=18 years of age with hiv-1 infection; * previously treated with antiretroviral agents. exclusion criteria: * prior use of fuzeon or t-1249; * inability to self-inject; * active, untreated opportunistic infection.
effectiveness of low-dose aspirin in prevention of cancer in the stomach and oesophagus (gastrointestinal cancer prevention) - united kingdom ("engage - uk"): study to evaluate the risk of cancer in the stomach and oesophagus among new users of low-dose aspirin using the thin database in the uk

Conditions: Prevention of Oesophagus Cancer and Stomach Cancer

Summary: researchers already did studies in low-dose aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. in this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose asa on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. to find this out electronic medical records stored in primary care database in the uk, the health improvement network (thin), will be used.


Eligibility criteria:
inclusion criteria: * aged 40-89 years * enrolled with the pcp for at least 2 years * to have a history of computerized prescriptions in thin for at least 1 year prior to start date exclusion criteria: * to be exposed to low-dose asa before entering in the study * having a diagnosis of any cancer before entering in the study
endorings™ assisted colonoscopy versus standard colonoscopy for polyp detection

Conditions: Colorectal Neoplasia; Intestinal Neoplasms; Digestive Neoplasms; Digestive System Disease; Intestinal Disease; Gastrointestinal Disease; Gastrointestinal Neoplasm

Summary: this study evaluates the impact of endorings™ assisted colonoscopy on the number of polyps detected per patient compared to standard colonoscopy without use of endorings™. half of the participants will receive endorings™ assisted colonoscopy, while the other half will receive standard colonoscopy.

colonoscopy is the gold standard for detection of colorectal neoplasia (polyps and cancers) but it is well known that colonoscopy is associated with a neoplasia miss rate of up to 25%. one such method of reducing the neoplasia miss rate is cap assisted colonoscopy, where a cap is placed at the distal end of the colonoscope.the theory behind how the cap aids mucosal visualisation is that it depresses and flattens colonic folds, thereby improving visualisation on the proximal sides of folds. investigators aim to evaluate the impact of one such cap assisted device: endorings™ on polyp detection rates. endorings™ has been shown to improve polyp detection rate by 51% compared to 29% for standard colonoscopy in a recent tandem endoscopy study. endorings™ has received fda approval.

Eligibility criteria:
inclusion criteria: * symptomatic patients referred for colonoscopy age ≥ 55. * asymptomatic patients age ≥55 undergoing screening or surveillance for polyps and cancers. exclusion criteria: * history of inflammatory bowel disease * history of hereditary non polyposis colorectal cancer (hnpcc) * familial adenomatous polyposis syndrome (fap) * hyperplastic polyposis syndrome * known colonic stricture

Keywords: endorings™